Kết quả tìm kiếm - Michael Bulitta
- Đang hiển thị 1 - 5 kết quả của 5
-
1
The Effect of an App-Based Home Exercise Program on Self-reported Pain Intensity in Unspecific and Degenerative Back Pain: Pragmatic Open-label Randomized Controlled Trial Bằng Hannes Weise, Benedikt P. Zenner, Bettina Schmiedchen, Leo Benning, Michael Bulitta, Daniel Schmitz, K. Weise
Được phát hành 2022Artigo -
2
-
3
Diclofenac patch for topical treatment of acute impact injuries: a randomised, double blind, placebo controlled, multicentre study Bằng Hans‐Georg Predel, Robert Koll, Helmut Pabst, Robert S. Dieter, G Gallacchi, Bruno Giannetti, Michael Bulitta, János L. Heidecker, E. Mueller
Được phát hành 2004Artigo -
4
Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial Bằng Peter Pickkers, Suzanne Heemskerk, Jeroen Schouten, Pierre-François Laterre, Jean‐Louis Vincent, Albertus Beishuizen, Philippe G. Jorens, Herbert Spapen, Michael Bulitta, Wilbert H.M. Peters, Johannes G. van der Hoeven
Được phát hành 2012Artigo -
5
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a mult... Bằng Beate Schultheis, Dirk Reuter, M. Ebert, Jens T. Siveke, Andrea Kerkhoff, Wolfgang E. Berdel, Ralf‐Dieter Hofheinz, Dirk Behringer, Wolfgang E. Schmidt, Erdem Göker, Sara De Dosso, Michael Kneba, Şuayib Yalçın, Friedrich Overkamp, Frank Schlegel, Markus Dommach, Robert Rohrberg, Tilmann Steinmetz, Michael Bulitta, Dirk Strumberg
Được phát hành 2017Artigo
Công cụ tìm kiếm:
Các môn học liên quan
Internal medicine
Medicine
Alternative medicine
Pathology
Randomized controlled trial
Placebo
Surgery
Alkaline phosphatase
Biochemistry
Chemistry
Enzyme
Gastroenterology
Acute kidney injury
Adverse effect
Analgesic
Anesthesia
Cancer
Chemotherapy
Clinical endpoint
Clinical trial
Colitis
Colorectal cancer
Czech
Diclofenac
Disease
Double blind
Emergency medicine
Epidermal growth factor receptor
Gemcitabine
Inflammatory bowel disease